Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7991761 | 0.83 | — | — | |
| SCHEMBL9613245 | 0.78 | — | — | |
| SCHEMBL1446029 | 0.78 | HTT (0.38) | DRD2FFAR3 | |
| SCHEMBL12409412 | 0.77 | ALDH1A1 (0.40) | DRD2FFAR3 | |
| SCHEMBL11955648 | 0.76 | HTT (0.41) | DRD2FFAR3 | |
| SCHEMBL5260246 | 0.76 | HTT (0.41) | DRD2FFAR3 | |
| SCHEMBL14627310 | 0.76 | HTT (0.41) | DRD2FFAR3 | |
| SCHEMBL5219364 | 0.76 | HTT (0.41) | DRD2FFAR3 | |
| SCHEMBL13204887 | 0.76 | POLB (0.45) | DRD2FFAR3 | |
| Hydrochloric Acid SCHEMBL20502497 | 0.74 | HTT (0.40) | DRD2FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0900083-B1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-08-20 | — | — | EP | claimed |
| EP-1314728-A1 | Pyridyl and pyrimidinyl imines as intermediates for imidazole derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-28 | — | — | EP | claimed |
| EP-0831830-B1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | claimed |
| EP-0889888-A4 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORP (US) | 2003-01-08 | — | — | EP | claimed |
| US-20020123500-A1 | Use of CSAIDTM compounds as inhibitors of angiogenesis | SMITHKLINE BEECHAM CORPORATION | 2002-09-05 | — | — | US | claimed |
| US-6387898-B1 | USING IMIDAZOLE COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2002-05-14 | — | — | US | claimed |
| US-6372741-B1 | ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2002-04-16 | — | — | US | claimed |
| US-6218537-B1 | Process for making pyridyl and pyrimidine substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION | 2001-04-17 | — | — | US | claimed |
| EP-0802908-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-04-11 | — | — | EP | claimed |
| US-6096739-A | Treatment for CNS injuries | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-01 | — | — | US | claimed |
| US-5756499-A | Substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1998-05-26 | — | — | US | claimed |
| EP-0831830-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0802908-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-29 | — | — | EP | claimed |
| WO-1997035856-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-02 | — | — | WO | claimed |
| WO-1997032583-A1 | USE OF CSAIDTM COMPOUNDS AS INHIBITORS OF ANGIOGENESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-12 | — | — | WO | claimed |
| US-5658903-A | Imidazole compounds, compositions and use | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-19 | — | — | US | claimed |
| WO-1997025047-A1 | NOVEL CYCLOALKYL SUBSTITUDED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | claimed |
| WO-1997025045-A1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | claimed |
| WO-1996040143-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996021654-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123500-A1 | Use of CSAIDTM compounds as inhibitors of angiogenesis | VEGFA, IL1RN, CXCL12 | DRD2 4069/4885FFAR3 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.